secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-09-08T11:33:18+00:00
Accession:  0001193125-26-384380
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q3 2026 net loss $32.5M; cash $266.3M; BLA filing on track for 4Q 2026
-----------------------------------------------------------------------------

- Net loss $32.5M ($0.47/share) vs $29.0M ($0.57/share) year ago; cash $266.3M.
- Total opex $34.0M vs $29.9M; R&D down $2.5M, G&A up $6.6M.
- Pivotal Cohort 1 data update, pre-BLA FDA meeting, and BLA initiation all planned for 4Q 2026.
- Surfactant cohort safety run-in cleared; KOL webinar on Oct 15, 2026.
- Michael Heffernan became Chairman in July 2026, succeeding Richard Glickman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/0001193125-26-384380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-384380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer